MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Day One Biopharmaceuticals, Inc.

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Tickers DAWN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story